Bristol Myers Squibb Reports Positive Phase 3 Camzyos Data for Adolescents

Bristol Myers Squibb (BMS) has announced positive results from its Phase 3 SCOUT-HCM trial, evaluating Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The data, presented at the American College of Cardiology (ACC) conference, confirms the drug's efficacy and safety in a younger patient demographic. Currently approved for adults, this successful trial supports the company's efforts to expand the clinical indications for the cardiovascular treatment. The findings reinforce Camzyos's position as a key growth driver within the BMS portfolio. Analysts view this development as a positive step toward securing regulatory approval for a broader patient base. This expansion could potentially increase the long-term market share of the drug in the global cardiology sector.